Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
10.82
-0.14 (-1.28%)
Sep 30, 2025, 5:31 PM CET
-1.28%
Market Cap215.98M
Revenue (ttm)55.93M
Net Income (ttm)23.65M
Shares Out19.96M
EPS (ttm)1.11
PE Ratio9.73
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume41,391
Average Volume100,804
Open11.00
Previous Close10.96
Day's Range10.66 - 11.00
52-Week Range5.20 - 11.00
Beta0.75
RSI66.91
Earnings DateSep 16, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 22
Stock Exchange SIX Swiss Exchange
Ticker Symbol NWRN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements